New Market Report: Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022

July 4, 2012 - PRLog -- GlobalData's pharmaceuticals report, "Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022" provides Rythmol SR global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/405096_rythmol_sr_atrial_fibrillation_analysis_and.aspx
------------------------------------------------------------

Scope

* Therapy area profile including patient population for the US market
* Analysis and review of Rythmol SR including sales data
* Qualitative and quantitative assessment of market space
* Analysis of the trends, drivers and restraints shaping and defining the markets
* In-depth analysis of Rythmol SR including efficacy, safety, pricing, competition and other details which influence its sales potential
* Global sales forecast for 2004 -2022 for Rythmol SR

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of competition by understanding the changing competitive landscape
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of the drug's performance
* Examine the historical sales performance of a drug in seven major markets
* Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

Rythmol SR, propafenone, anti-arrhythmics, rapid heartbeats, atrial arrhythmias, ventricular arrhythmias, short-life

Report Table of Contents:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Atrial Fibrillation Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.3.1 Symptoms associated with AF
2.4 GlobalData Analysis and Forecasts Report Guidance
3 Atrial Fibrillation: Market Characterization
3.1 Atrial Fibrillation Market
3.2 Atrial Fibrillation Market Forecasts and CAGR
3.3 Drivers of Atrial Fibrillation Market
3.3.1 High Unmet need
3.3.2 Strong Pipeline
3.3.3 Increase in prevalence and ageing populations
3.3.4 Organisation of Awareness Campaigns
3.4 Barriers in Atrial Fibrillation Market
3.4.1 Limitations in established therapies
3.4.2 High cost of emerging therapies
4 Classification in Atrial Fibrillation: Introduction
4.1 AF Classification
4.1.1 Pathophysiology of AF
4.1.2 Diagnosis in Atrial Fibrillation
4.1.3 Impact of Atrial Fibrillation
5 Treatment Options and Management in Atrial Fibrillation
5.1 Rate control and Rhythm control
5.2 Rate Control Versus Rhythm Control
6 Rythmol SR
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.4 Approval Status of Rythmol SR
6.5 Factors Affecting Sales of Rythmol SR
6.5.1 Unique Profile with efficacy, safety and dosing profile
6.5.2 Entry of Generics
6.6 Drug Evaluation
6.6.1 Drug Risk Benefit Score
6.6.2 Intensity of Competition
6.7 Sales Forecasts
6.7.1 Target Patient Pool of Rythmol SR
6.7.2 Dosing
6.7.3 Market Penetration
6.7.4 Annual Cost of Therapy
6.7.5 Sales Projections of Rythmol SR
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to Take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

List of Tables

1.1 List of Tables
Table 1: Epidemiology of Atrial Fibrillation (2011)
Table 2: Increase in the Risk of AF in The Presence of Risk Factors
Table 3: Stratification of All Risk Factors For Atrial Fibrillation
Table 4: Atrial Fibrillation Classification
Table 5: Treatment Guidelines For the Management of Atrial Fibrillation
Table 6: Rythmol SR, Approval Status
Table 7: Drug Risk Benefit Score of Rythmol SR
Table 8: Rythmol SR, Atrial Fibrilation, Global, Cost of Therapy, 2011
Table 9: Rythmol SR, Atrial Fibrillation, The US, Sales Forecasts ($m), 2004-2012
Table 10: Rythmol SR, Atrial Fibrillation, The US, Sales Forecasts ($m), 2013-2022

List of Figures

1.2 List of Figures
Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011-2022
Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation
Figure 3: Increase of Prevalance Population in Atrial Fibrillation
Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation
Figure 5: Broad classification of Patterns in Atrial Fibrillation
Figure 6: Disease States Associated with Atrial Fibrillation, By (%)
Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF)
Figure 8: Management of Newly Discovered Atrial Fibrillation (AF)
Figure 9: Drug Model Diagram of Rythmol SR
Figure 10: Rythmol SR, Atrial Fibrillation, The US, Sales Forecasts ($m), 2004-2022
Figure 11: Patients Approved for the Drug

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.